CDK4 and CDK6

Assets acting on this target.

Class
CDK4/6 inhibitor (small molecule)
Pathway
Blocks retinoblastoma protein (Rb) phosphorylation, halting G1-to-S cell-cycle progression

CDK4 and CDK6 (cyclin-dependent kinases 4 and 6) are enzymes that, in partnership with D-type cyclin proteins, govern whether a cell advances from its resting growth phase into the phase where it copies its DNA and prepares to divide. Active CDK4/6 adds phosphate groups to the retinoblastoma protein (Rb), releasing transcription factors that switch on genes needed for DNA replication. Many cancers, particularly those driven by hormone-receptor signaling, exploit this pathway by increasing cyclin D levels or losing natural brakes on CDK4/6, so cells divide without normal restraint. Small-molecule inhibitors of CDK4/6 block the phosphorylation step, keeping Rb in its growth-suppressing state and holding susceptible cells in the resting phase rather than allowing them to divide. Because CDK4/6 activity is also needed for turnover of some healthy tissues, particularly bone marrow progenitor cells and gut lining, inhibition predictably affects these tissues as well, producing manageable, reversible on-target effects. This mechanism is broadly important in cancers where cell division depends heavily on this checkpoint, and more generally illustrates how targeting cell-cycle regulators, rather than a specific cancer driver mutation, can slow proliferation across tumor types that share this dependency.

By indication

Related mechanisms

CDK4 and CDK6 drugs compared

6 drugs, stage by indication
6 drugs acting on CDK4 and CDK6: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
AbemaciclibVerzenioEli Lillysmall moleculeApprovedApproved in Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer; Phase 2 in Glioma
PalbociclibIbrancePfizersmall moleculeApprovedApproved in Breast Cancer; Approved in HER2-Positive Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer
RibociclibNovartissmall moleculeApprovedApproved in Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer
DalpiciclibJiangsu Hengrui Pharmaceuticalssmall moleculePhase 3Phase 3 in HR+/HER2- Metastatic Breast Cancer
TibremciclibKangmeinaBetta Pharmaceuticals Co.small moleculePhase 3Phase 3 in HR+/HER2- Metastatic Breast Cancer
SPH4336Shanghai Pharmaceuticals Holdingsmall moleculePhase 2/3Phase 2/3 in HR+/HER2- Metastatic Breast Cancer

← all mechanisms